Editor’s Note: The following is a summary of one of the talks from the 2013 Nano-bio Symposium hosted by Johns Hopkins Institute for NanoBioTechnology held May 17. This summary was written by Randall Meyer, a doctoral candidate in the biomedical engineering and a member of the Cancer Nanotechnology Training Center. Look for other symposium summaries on the INBT blog.
Among many of the therapies developed over the past several years, stem cells remain one of the most promising for purposes of regeneration, autoimmune disease, and cancer treatment.
Gabrielle Todd, a senior scientist at Osiris Therapeutics, explained some the new mesenchymal stem cell (MSC) based therapies that the company has been developing over the past several years during her talk at the annual Nano-Bio Symposium, hosted by Johns Hopkins Institute for NanoBioTechnology.
The key features that make MSCs such an attractive option is their ability to be isolated from a patient, expanded ex vivo, and re-infused into the same or possibly a different patient. Once inside the body they will home to the site of trouble and release anti-inflammatory and regenerative signals to the damaged tissue. In addition, these cells are what is known as “immune privileged,” in that they lack the necessary signals to trigger an immune response, customary in other transfusions.
Todd summarized some applications on which the company is currently working. One is an MSC-based therapy that utilizes the unique properties of these cells to treat a wide variety of immune related diseases such as graft vs. host disease, Crohn’s disease, and tissue damage from cardiac arrest to juvenile diabetes.
A second application is a product that utilizes MSCs immobilized in a membrane and applied to the site of an external wound. This cells then mediate regeneration of the external tissues, allowing for more efficient healing.
Todd reports that some of these therapies could be available on the market in the coming years.